What is the debt of Regeneron Pharmaceuticals this year?
Regeneron Pharmaceuticals has a debt level of -13,538.4 USD this year.
In 2024, Regeneron Pharmaceuticals's total debt was -13,538.4 USD, a 3,242.81% change from the -405 USD total debt recorded in the previous year.
In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.
Regeneron Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Analyzing Regeneron Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Investors pay close attention to Regeneron Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Shifts in Regeneron Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Regeneron Pharmaceuticals has a debt level of -13,538.4 USD this year.
The debt of Regeneron Pharmaceuticals has increased by 3,242.81% compared to the previous year increased.
High debt can pose a risk for investors of Regeneron Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
Low debt means that Regeneron Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.
An increase in debt of Regeneron Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.
A reduction in debt of Regeneron Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.
Some factors that can influence the debt of Regeneron Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.
The debts of Regeneron Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
To change the debt, Regeneron Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.
The current dividend yield of Regeneron Pharmaceuticals is .
Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
Regeneron Pharmaceuticals paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Regeneron Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of Regeneron Pharmaceuticals from 5/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.
The last dividend was paid out on 5/15/2024.
In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.
The dividends of Regeneron Pharmaceuticals are distributed in USD.
The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.